Success and Failures of Combined Modalities in Glioblastoma Multiforme: Old Problems and New Directions.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 27619250.
- Also identified by DOI 10.1016/j.semradonc.2016.06.003.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Glioblastoma multiforme (GBM) is an aggressive intracranial tumor characterized by local and distant brain relapse despite aggressive therapy. Current standard treatment includes surgical resection followed by radiation with concurrent and adjuvant temozolomide as part of a combined modality approach. In this review, the historical basis for the current standard treatment is discussed as well as other recent combined modality successes and failures. An overview of emerging combined modality therapies for GBM is presented including immunotherapy, and rationally designed radiosensitizers. Unanswered questions facing the oncology community regarding the treatment of GBM are also discussed.
Medical subject headings
- Brain Neoplasms
- Glioblastoma